Novartis has announced the opening of its Phase I/II CYStem clinical trial, recruiting children ages 2-5 with nephropathic cystinosis. The trial will evaluate the safety and efficacy of their cellular gene therapy treatment. For more information via the clinical trials website click here. You can also learn more about the study through Novartis’ community statement here.